Eupraxia Pharmaceuticals (EPRX) Total Debt (2022 - 2024)

Eupraxia Pharmaceuticals (EPRX) has 3 years of Total Debt data on file, last reported at $21209.0 in Q2 2024.

• On a quarterly basis, Total Debt changed N/A year-over-year to $21209.0 in Q2 2024; TTM through Jun 2024 was $21209.0, a N/A change from a year earlier, with the FY2023 full-year figure at $10.4 million, up 7216.49% from the prior year.
• Total Debt for Q2 2024 stood at $21209.0, down from $42112.0 in the prior quarter.
• Over the last five years, Total Debt for EPRX reached as high as $10.4 million in Q4 2023 and fell as low as $21209.0 in Q2 2024.
• Historically, Total Debt has averaged $2.7 million across 3 years, with a median of $92119.5 in 2022.
• On a YoY basis, Total Debt climbed as much as 7216.49% in 2023 and fell as far as 7216.49% in 2023.
• Year by year, Total Debt stood at $142127.0 in 2022, then soared by 7216.49% to $10.4 million in 2023, then tumbled by 99.8% to $21209.0 in 2024.
• Per Business Quant data, the three most recent Total Debt figures were $21209.0 in Q2 2024, $42112.0 in Q1 2024, and $10.4 million in Q4 2023.